ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Endocrinology, Diabetes Metabolism

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

14,367Medicare Part D Prescriptions Filled, Including Refills

Rank: 3 out of 208

$1.86M Total Retail Price of All Prescriptions

Rank: 1 out of 208

535 Patients Receiving at Least One Drug in Part D
51%Patients 65 Years and Older
84% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Pennsylvania
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

5% of this provider’s 535 patients filled at least one prescription for a schedule three drug, compared to an average of 2%.

Risky Drugs to Seniors

0% of this provider’s 7,572 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

46% of this provider’s prescriptions were for brand-name drugs, compared to an average of 51%.

Prescription Price

$129 was the average price of a prescription from this provider, compared to $143 among peers.

Prescriptions per Patient

27 is the average number of prescriptions (including refills) per patient, compared to an average of 10.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Pennsylvania
LEVOTHYROXINE SODIUM 747 308 1 1
JANUMET 731 328 10 2 28
PEN NEEDLE 604 307 3 3
LOVASTATIN 601 328 4 59
GLIMEPIRIDE 589 350 5 10
HUMALOG 575 204 10 6 8
LANTUS SOLOSTAR 498 242 7 5
LISINOPRIL 482 244 8 14
JANUVIA 471 272 9 12
CARVEDILOL 439 254 10 47
AMLODIPINE BESYLATE 411 262 11 20
NIASPAN 391 146 12 52
SIMVASTATIN 373 184 13 6
TERAZOSIN HCL 327 226 14 93
METFORMIN HCL 276 144 15 4
LEVEMIR FLEXPEN 258 134 16 19
NOVOLOG FLEXPEN 250 119 17 11
FUROSEMIDE 240 151 18 24
LISINOPRIL-HYDROCHLOROTHIAZIDE 239 115 19 79
ATORVASTATIN CALCIUM 231 110 20 15
METOPROLOL TARTRATE 218 135 21 33
LANTUS 215 88 22 7
SYNTHROID 213 119 23 2
NOVOLOG 177 90 24 18
METFORMIN HCL ER 168 98 25 13
PRAVASTATIN SODIUM 155 106 26 27
INSULIN SYRINGE 147 54 27 9
ALENDRONATE SODIUM 145 97 28 32
HYDROCHLOROTHIAZIDE 130 75 29 29
LOSARTAN POTASSIUM 125 75 30 34
CRESTOR 125 83 30 31
METHIMAZOLE 121 78 32 17
FENOFIBRATE 120 26 33 43
ZETIA 120 57 33 30
CLONIDINE 118 87 35 144
ULORIC 115 69 36 146
AMLODIPINE BESYLATE-BENAZEPRIL 113 69 37 77
BYETTA 110 67 38 41
ALLOPURINOL 109 64 39 84
LEVOXYL 109 31 39 16
LEVEMIR 107 26 41 55
EXFORGE HCT 98 78 42 156
SURE COMFORT 85 51 43 124
ACTONEL 82 60 44 75
ZEMPLAR 78 59 45 128
LOSARTAN-HYDROCHLOROTHIAZIDE 74 16 46 106
AMMONIUM LACTATE 74 41 46 170
BENICAR HCT 70 60 48 102
VICTOZA 3-PAK 69 30 49 44
EXFORGE 68 50 50 116
ACTOPLUS MET 63 45 51 138
BENAZEPRIL HCL 62 35 52 130
HUMALOG MIX 75-25 61 45 53 25
LOVAZA 57 0 54 39
IBANDRONATE SODIUM 54 52 55 192
AZOR 52 0 56 151
TESTOSTERONE CYPIONATE 52 19 S3 56 198
BYSTOLIC 50 46 58 207
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 7, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.